SynthesisBMC infectious diseases2017
Estimation of the burden of varicella in Europe before the introduction of universal childhood immunization.
Synthesis in BMC infectious diseases, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
49 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Healthcare resource use and costs of varicella and its complications: A systematic literature review.Human vaccines & immunotherapeutics · 2023Pooled it
- Economic burden of varicella in Europe in the absence of universal varicella vaccination.BMC public health · 2021Pooled it
- A systematic review of varicella seroprevalence in European countries before universal childhood immunization: deriving incidence from seroprevalence data.Epidemiology and infection · 2017Pooled it
- Immunogenicity and safety of a live attenuated varicella vaccine in children aged 1 to 12 years: A double-blind, randomized, parallel-controlled phase III clinical trial in China.Human vaccines & immunotherapeutics · 2025Trial
- Randomised controlled trial showed long-term efficacy, immunogenicity and safety of varicella vaccines in Norwegian and Swedish children.Acta paediatrica (Oslo, Norway : 1992) · 2022Trial
- Clinically- versus serologically-identified varicella: A hidden infection burden. A ten-year follow-up from a randomized study in varicella-endemic countries.Human vaccines & immunotherapeutics · 2021Trial
- Global burden of varicella and herpes zoster in women of childbearing age: insights from the global burden of disease study 1990-2021.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Article
- Varicella zoster virus infection.Nature reviews. Disease primers · 2026Review
- Estimating the Long-Term Clinical and Economic Impact of Universal Varicella Vaccination in Portugal Using a Dynamic Transmission Model.PharmacoEconomics - open · 2026Article
- Modeling the clinical and economic impact of universal varicella vaccination in Belgium with dynamic population.PLOS global public health · 2026Article
- Article
- Trends and patterns of varicella zoster virus infection in Kilifi: A population-based serosurvey.PLOS global public health · 2026Article
- Article
- Estimating the Burden of Mild-to-Moderate Varicella-Related Infections by Medical Helpline Usage: A Time Series Analysis from 2015 to 2023 Among Children in Denmark.Infectious diseases and therapy · 2025Article
- Factors associated with mortality in immunocompromised children with varicella.BMC pediatrics · 2025Article
- The impact of the implementation of the two-dose varicella vaccine immunization strategy in Quzhou: A retrospective birth cohort study.Human vaccines & immunotherapeutics · 2024Article
- Logistic and organizational barriers to herpes zoster vaccination in europe: A systematic review.Vaccine: X · 2024Review
- Immunity to Varicella Zoster Virus in Healthcare Workers: A Systematic Review and Meta-Analysis (2024).Vaccines · 2024Review
- The Clinical and Economic Burden of Antibiotic Use in Pediatric Patients With Varicella Infection: A Retrospective Cohort Analysis of Real-World Data in England.The Journal of infectious diseases · 2024Article
- The clinical and economic costs associated with regional disparities in varicella vaccine coverage in Italy over 50 years (2020-2070).Scientific reports · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundVaricella is generally considered a mild disease. Disease burden is not well known and country-level estimation is challenging. As varicella disease is not notifiable, notification criteria and rates vary between countries. In general, existing surveillance systems do not capture cases that do not seek medical care, and most are affected by underreporting and underascertainment. We aimed to estimate the overall varicella disease burden in Europe to provide critical information to support decision-making regarding varicella vaccination.
methodsWe conducted a systematic literature review to identify all available epidemiological data on varicella IgG antibody seroprevalence, primary care and hospitalisation incidence, and mortality. We then developed methods to estimate age-specific varicella incidence and annual number of cases by different levels of severity (cases in the community, health care seekers in primary care and hospitals, and deaths) for all countries belonging to the European Medicines Agency (EMA) region and Switzerland.
resultsIn the absence of universal varicella immunization, the burden of varicella would be substantial with a total of 5.5 million (95% CI: 4.7-6.4) varicella cases occurring annually across Europe. Variation exists between countries but overall the majority of cases (3 million; 95% CI: 2.7-3.3) would occur in children <5 years. Annually, 3-3.9 million patients would consult a primary care physician, 18,200-23,500 patients would be hospitalised, and 80 varicella-related deaths would occur (95% CI: 19-822).
conclusionsVaricella disease burden is substantial. Most cases occur in children <5 years old but adults require hospitalisation more often and are at higher risk of death. This information should be considered when planning and evaluating varicella control strategies. A better understanding of the driving factors of country-specific differences in varicella transmission and health care utilization is needed. Improving and standardizing varicella surveillance in Europe, as initiated by the European Centre for Disease Prevention and Control (ECDC), is important to improve data quality to facilitate inter-country comparison.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.